{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:06:08Z","timestamp":1791569168838,"version":"4.3.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background and Objective<\/jats:title><jats:p>Relevant data of PARADIGM-HF reveals sacubitril\/valsartan (SV) therapy led to a greater reduction in the risks of arrhythmia, and sudden cardiac death than angiotensin converting enzyme inhibitor (ACEI)\/angiotensin receptor inhibitor (ARB) therapy in HFrEF, however, inconsistent results were reported in subsequent studies. Here, we conduct a meta-analysis of related randomized controlled trials (RCTs) to evaluate the protective effect of SV on reducing the risk of arrhythmias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>RCTs focused on the difference in therapeutic outcomes between SV and ACEI\/ARB were searched from PUBMED, EMBASE, <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, and Cochrane Library. The results were extracted from each individual study, expressed as binary risk, 95% confidence interval (CI) and relative risk (RR). Sixteen RCTs including 22, 563 patients met the study criteria. Compared with ACEI\/ARB therapy, SV therapy did significantly reduce in the risks of severe arrhythmias among patients with heart failure with reduced ejection fraction (HFrEF) (RR 0.83, 95% CI 0.73\u20130.95, <jats:italic>p<\/jats:italic> = 0.006), ventricular tachycardia (VT) among patients with HFrEF (RR 0.69, 95% CI 0.51\u20130.92, <jats:italic>p<\/jats:italic> = 0.01), cardiac arrest among patients with heart failure (HF) (RR 0.52, 95% CI 0.37\u20130.73, <jats:italic>p<\/jats:italic> = 0.0002), cardiac arrest among patients with HFrEF (RR 0.49, 95% CI 0.32\u20130.76, <jats:italic>p<\/jats:italic> = 0.001), cardiac arrest or ventricular fibrillation (VF) among patients with HF (RR 0.63, 95% CI 0.48\u20130.83, <jats:italic>p<\/jats:italic> = 0.001), and cardiac arrest or VF among patients with HFrEF (RR 0.65, 95% CI 0.47\u20130.89, <jats:italic>p<\/jats:italic> = 0.008), but reduced the risks of arrhythmias (RR 0.87, 95% CI 0.74\u20131.01, <jats:italic>p<\/jats:italic> = 0.07), atrial arrhythmias (RR 0.98, 95% CI 0.83\u20131.16, <jats:italic>p<\/jats:italic> = 0.85), and atrial fibrillation (RR 0.98, 95% CI 0.82\u20131.17, <jats:italic>p<\/jats:italic> = 0.82) among all patients with no significant between-group difference. The merged result was robust after sensitivity analysis, and there was no publication bias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our meta-analysis provides evidence that, compared with ACEI\/ARB, SV can additionally reduce the risks of most arrhythmias, just the significant differences are revealed in reducing the risks of VT, severe arrhythmias, and cardiac arrest in patients with HFrEF. Besides, the positive effect of SV on VF according to statistical result of combining VF with cardiac arrest in patients with HFrEF is credibility.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.890481","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:34:05Z","timestamp":1656938045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Sacubitril\/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"9","author":[{"given":"Ruxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0735-6757(95)90095-0","article-title":"Cardiac arrhythmia diagnosis.","volume":"13","author":"Vukmir","year":"1995","journal-title":"Am J Emerg Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/j.jacc.2019.02.045","article-title":"Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Huizar","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham heart study: a cohort study.","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association[J].","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.mcna.2012.07.007","article-title":"Atrial fibrillation in heart failure.","volume":"96","author":"Lardizabal","year":"2012","journal-title":"Med Clin North Am."},{"key":"B6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1161\/circulationaha.116.025312","article-title":"Atrial fibrillation and ventricular arrhythmias: sex differences in electrophysiology, epidemiology, clinical presentation, and clinical outcomes.","volume":"135","author":"Gillis","year":"2017","journal-title":"Circulation."},{"key":"B7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccl.2013.09.005","article-title":"Arrhythmias and heart failure.","volume":"32","author":"Saltzman","year":"2014","journal-title":"Cardiol Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fcvm.2020.00126","article-title":"Future perspectives and new \u201cFrontiers\u201d in cardiac rhythmology.","volume":"7","author":"Anselmino","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/nejmoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1093\/eurheartj\/ehab627","article-title":"The ESC guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.","volume":"42","author":"Crea","year":"2021","journal-title":"Eur Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/jcm9041111","article-title":"The effect of sacubitril\/valsartan on device detected arrhythmias and electrical parameters among dilated cardiomyopathy patients with reduced ejection fraction and implantable cardioverter defibrillator.","volume":"9","author":"Russo","year":"2020","journal-title":"J Clin Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jjcc.2021.04.011","article-title":"Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia.","volume":"78","author":"Tsai","year":"2021","journal-title":"J Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ejhf.2419","article-title":"Effect of sacubitril\/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.","volume":"24","author":"Curtain","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3389\/fphar.2019.01285","article-title":"Sacubitril\/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice.","volume":"10","author":"Suo","year":"2019","journal-title":"Front Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12265-021-10137-5","article-title":"Sacubitril\/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin II-induced atrial fibrosis through p-Smad2\/3, p-JNK, and p-p38 signaling pathways.","volume":"15","author":"Li","year":"2022","journal-title":"J Cardiovasc Transl Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/jcm8101582","article-title":"Impact of sacubitril\/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients.","volume":"8","author":"El-Battrawy","year":"2019","journal-title":"J Clin Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMx190009","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure.","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.enfi.2020.12.001","article-title":"Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions.","volume":"32","author":"Page","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2307\/2982993","article-title":"Publication bias: a problem in interpreting medical data.","volume":"181","author":"Begg","year":"1988","journal-title":"J R Stat Soc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/ajh\/hpx111","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (=65 Years) with systolic hypertension.","volume":"30","author":"Supasyndh","year":"2017","journal-title":"Am J Hypertens."},{"key":"B27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/hypertensionAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study.","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jch.13437","article-title":"Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study.","volume":"21","author":"Huo","year":"2019","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"B31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41440-021-00819-7","article-title":"Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.","volume":"45","author":"Rakugi","year":"2022","journal-title":"Hypertens Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1002\/ejhf.2355","article-title":"A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study.","volume":"23","author":"Halle","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07315-1","article-title":"Sacubitril\/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation.","author":"Wang","year":"2022","journal-title":"Cardiovasc Drugs Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/MCA.0000000000000932","article-title":"Effects of sacubitril\/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction.","volume":"32","author":"Wang","year":"2021","journal-title":"Coron Artery Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/circulationAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation.","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation."},{"key":"B36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ejhf.207","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.","volume":"23","author":"Piepoli","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"B37","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction- results from the PARALLEL-HF study.","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial.","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/circulationAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation: the PRIME study.","volume":"139","author":"Kang","year":"2018","journal-title":"Circulation."},{"key":"B40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/cphy.c140055","article-title":"Pathophysiology of heart failure.","volume":"6","author":"Tanai","year":"2015","journal-title":"Compr Physiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.15420\/cfr.2018.20.2","article-title":"Calming the nervous heart: autonomic therapies in heart failure.","volume":"4","author":"Hanna","year":"2018","journal-title":"Card Fail Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6515\/acs20151120a","article-title":"Critical questions about PARADIGM-HF and the future.","volume":"32","author":"Chen","year":"2016","journal-title":"Acta Cardiol Sin."},{"key":"B43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.","volume":"19","author":"Diez","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6032631","DOI":"10.1155\/2019\/6032631","article-title":"LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model.","volume":"2019","author":"Chang","year":"2019","journal-title":"Cardiovasc Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/circheartfailure.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail."},{"key":"B46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41540-017-0013-4","article-title":"Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: a systems biology approach.","volume":"3","author":"Iborra-Egea","year":"2017","journal-title":"NPJ Syst Biol Appl."},{"key":"B47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/CIRCEP.107.754788","article-title":"Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure.","volume":"1","author":"Yeh","year":"2008","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1152\/physrev.00014.2006","article-title":"Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation.","volume":"87","author":"Nattel","year":"2007","journal-title":"Physiol Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.hrthm.2014.04.024","article-title":"B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias.","volume":"11","author":"Levine","year":"2014","journal-title":"Heart Rhythm."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/circresaha.117.310083","article-title":"Calcium signaling and cardiac arrhythmias.","volume":"120","author":"Landstrom","year":"2017","journal-title":"Circ Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1002\/ehf2.13013","article-title":"Reverse electromechanical modelling of diastolic dysfunction in spontaneous hypertensive rat after sacubitril\/valsartan therapy.","volume":"7","author":"Sung","year":"2020","journal-title":"ESC Heart Fail."},{"key":"B52","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cardfail.2020.03.007","article-title":"Sacubitril\/valsartan therapy ameliorates ventricular tachyarrhythmias inducibility in a rabbit myocardial infarction model.","volume":"26","author":"Chang","year":"2020","journal-title":"J Card Fail."},{"key":"B53","doi-asserted-by":"publisher","first-page":"652163","DOI":"10.3389\/fphys.2021.652163","article-title":"Sacubitril\/valsartan as a therapeutic tool across the range of heart failure phenotypes and ejection fraction spectrum.","volume":"12","author":"Gallo","year":"2021","journal-title":"Front Physiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/circulationAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure.","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation."},{"key":"B55","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction.","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/s0735-1097(87)80220-6","article-title":"Frequency and significance of ventricular arrhythmia in patients with reduced ejection fraction (less than or equal to 30%).","volume":"10","author":"Krebs","year":"1987","journal-title":"J Am Coll Cardiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.hrthm.2013.03.018","article-title":"Arrhythmia and left ventricular ejection fraction: once broken, always broken?","volume":"10","author":"Linton","year":"2013","journal-title":"Heart Rhythm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/0735-1097(94)00553-3","article-title":"Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the cardiac arrhythmia suppression trial.","volume":"25","author":"Hallstrom","year":"1995","journal-title":"J Am Coll Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijcard.2016.06.197","article-title":"Left atrial strain: a useful index in atrial fibrillation.","volume":"220","author":"Cameli","year":"2016","journal-title":"Int J Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.890481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:34:11Z","timestamp":1656938051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.890481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":59,"alternative-id":["10.3389\/fcvm.2022.890481"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.890481","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"890481"}}